Health & Environmental Research Online (HERO)


Print Feedback Export to File
1295910 
Journal Article 
A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB) 
Loprinzi, CL; Dueck, AC; Khoyratty, BS; Barton, DL; Jafar, S; Rowland, KM; Atherton, PJ; Marsa, GW; Knutson, WH; Bearden, JD; Kottschade, L; Fitch, TR 
2009 
Yes 
Annals of Oncology
ISSN: 0923-7534
EISSN: 1569-8041 
20 
3 
542-549 
English 
19129205 
INTRODUCTION: Hot flashes represent a significant problem in men undergoing androgen deprivation therapy.

MATERIALS AND METHODS: Via a prospective, double-blind, placebo-controlled clinical trial, men with hot flashes, on a stable androgen deprivation therapy program for prostate cancer, received a placebo or gabapentin at target doses of 300, 600, or 900 mg/day. Hot flash frequencies and severities were recorded daily during a baseline week and for 4 weeks while the patients took the study medication.

RESULTS: In the 214 eligible patients who began the study drug on this trial, comparing the fourth treatment week to the baseline week, mean hot flash scores decreased in the placebo group by 4.1 units and in the three increasing dose gabapentin groups by, 3.2, 4.6, and 7.0 units. Comparing the three combined gabapentin arms to the placebo arm did not result in significant hot flash differences. Wilcoxon rank-sum P values for change in hot flash scores and frequencies after 4 weeks of treatment were 0.10 and 0.02, comparing the highest dose gabapentin arm to the placebo arm, respectively. The gabapentin was well tolerated in this trial.

CONCLUSION: These results support that gabapentin decreases hot flashes, to a moderate degree, in men with androgen ablation-related vasomotor dysfunction.